rs587778340
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_022725.4(FANCF):c.484_485delCT(p.Leu162AspfsTer103) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000159 in 1,614,136 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_022725.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000125 AC: 19AN: 152256Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000759 AC: 19AN: 250260Hom.: 0 AF XY: 0.000110 AC XY: 15AN XY: 135758
GnomAD4 exome AF: 0.000163 AC: 238AN: 1461880Hom.: 0 AF XY: 0.000162 AC XY: 118AN XY: 727240
GnomAD4 genome AF: 0.000125 AC: 19AN: 152256Hom.: 0 Cov.: 33 AF XY: 0.000148 AC XY: 11AN XY: 74380
ClinVar
Submissions by phenotype
Fanconi anemia complementation group F Pathogenic:5
- -
The FANCF c.484_485del; p.Leu162AspfsTer103 (rs587778340) is reported in the literature in the compound heterozygous and homozygous states in at least nine individuals (including three siblings) affected with Fanconi anemia (Chandra 2005, Chandrasekharappa 2013, Muramatsu 2017, Nicchia 2015, Tryon 2017). This variant is also reported in ClinVar (Variation ID: 6343). This variant is found in the non-Finnish European population with an allele frequency of 0.01% (14/128732) alleles) in the Genome Aggregation Database (v2.1.1). In vitro functional analyses demonstrate this mutant results in absent FANCF protein (de Winter 2000). This variant results in a premature termination codon in a single-exon gene. While this may not lead to nonsense-mediated decay, it is expected to create a truncated FANCF protein that would include a sequence of 102 amino acid residues not usually present. Based on available information, this variant is considered to be pathogenic. References: Chandra S et al. A rapid method for retrovirus-mediated identification of complementation groups in Fanconi anemia patients. Mol Ther. 2005 Nov. PMID: 16084127. Chandrasekharappa SC et al. Massively parallel sequencing, aCGH, and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia. Blood. 2013 May 30. PMID: 23613520. de Winter JP et al. The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nature genetics. 2000 Jan. PMID: 10615118. Muramatsu H et al. Clinical utility of next-generation sequencing for inherited bone marrow failure syndromes. Genet Med. 2017 Jul. PMID: 28102861. Nicchia E et al. Clinical aspects of Fanconi anemia individuals with the same mutation of FANCF identified by next generation sequencing. Birth Defects Res A Clin Mol Teratol. 2015 Dec. PMID: 26033879. Tryon R et al. Phenotypic variability in patients with Fanconi anemia and biallelic FANCF mutations. Am J Med Genet A. 2017 Jan. PMID: 27714961. -
- -
The FANCF c.484_485delCT (p.Leu162AspfsTer103) variant results in a frameshift, and is predicted to cause premature termination of the protein. The p.Leu162AspfsTer103 variant has been reported in three studies in which it is found in a total of six patients with Fanconi anemia including in four in homozygous state (including three sibling fetuses terminated for congenital anomalies), and in two in a compound heterozygous state (de Winter et al. 2000; Nicchia et al. 2015; Chandra et al. 2005). Control data are unavailable for this variant, which is reported at a frequency of 0.00024 in the South Asian population of the Exome Aggregation Consortium. The FANCF protein was absent in lymphoblasts from an individual who was homozygous for the variant (de Winter et al. 2000). Due to the potential impact of frameshift variants and the collective evidence, the p.Leu162AspfsTer103 variant is classified as pathogenic for Fanconi anemia. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -
- -
Fanconi anemia Pathogenic:3
- -
This sequence change creates a premature translational stop signal (p.Leu162Aspfs*103) in the FANCF gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 213 amino acid(s) of the FANCF protein. This variant is present in population databases (rs587778340, gnomAD 0.02%). This premature translational stop signal has been observed in individuals with Fanconi anemia (FA) (PMID: 26033879, 27714961, 28102861). ClinVar contains an entry for this variant (Variation ID: 6343). Algorithms developed to predict the effect of variants on gene product structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects FANCF function (PMID: 10615118). For these reasons, this variant has been classified as Pathogenic. -
Variant summary: FANCF c.484_485delCT (p.Leu162AspfsX103) results in a premature termination codon, predicted to cause a truncation of the encoded protein but not expected to result in nonsense mediated decay. The variant allele was found at a frequency of 7.6e-05 in 250260 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in FANCF causing Fanconi Anemia (7.6e-05 vs 0.0004), allowing no conclusion about variant significance. c.484_485delCT has been reported in the literature in multiple individuals affected with Fanconi Anemia (example: Chandrasekharappa_2013, Wang_2023, Nicchia _2015). These data indicate that the variant is very likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 23613520, 36513378, 26033879). ClinVar contains an entry for this variant (Variation ID: 6343). Based on the evidence outlined above, the variant was classified as pathogenic. -
not provided Pathogenic:1
Reported with a second FANCF variant in multiple individuals with Fanconi anemia (PMID: 27714961); Published functional studies demonstrate disruption of protein expression (PMID: 10615118); Frameshift variant predicted to result in abnormal protein length as the last 213 amino acids are replaced with 102 different amino acids, and other similar variants have been reported in HGMD; This variant is associated with the following publications: (PMID: 16084127, 28102861, 10615118, 28687971, 26689913, 34426522, 31589614, 34117267, 34308104, 36200007, 26033879, 27714961) -
FANCF-related disorder Pathogenic:1
The FANCF c.484_485delCT variant is predicted to result in a frameshift and premature protein termination (p.Leu162Aspfs*103). This variant has been reported as a cause of Fanconi anemia in several patients (de Winter et al. 2000. PubMed ID: 10615118; Tryon et al. 2016. PubMed ID: 27714961; Muramatsu et al. 2017. PubMed ID: 28102861; https://databases.lovd.nl/shared/variants/FANCF/). This variant is reported in 0.023% of alleles in individuals of South Asian descent in gnomAD. This variant is classified as pathogenic by multiple submitters in Clinvar (https://www.ncbi.nlm.nih.gov/clinvar/variation/6343/). Frameshift variants in FANCF are expected to be pathogenic. This variant is interpreted as pathogenic. -
not specified Other:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at